It makes molecules other companies cannot, or will not, make themselves — and it has just been picked by Dow to invent a way of making silicones in India. Aether Industries is a Surat contract chemistry business, thirteen years old and listed since 2022. It works three ways: research and manufacturing for a client (CRAMS), dedicated exclusive manufacturing under long-term contracts (CEM), and its own large-scale molecules (LSM). The first two are now 60% of revenue and management wants 70% within a couple of years. Year to March 2026: revenue ₹1,160 crore, up 38%, and profit ₹219 crore, up 39%. EBITDA margin 31.3%, up from 28.8%. June 2026 quarter: revenue ₹327 crore, up 27%, with CEM up about 75% and CRAMS about 20%. The customer list is the evidence. Baker Hughes has a plant of its own here and bought ₹70 crore in the quarter. Saudi Aramco co-developed a polyol. Milliken signed a multi-year supply agreement. On 30 July 2026, Dow made Aether its exclusive Indian research partner for new ways of manufacturing silicones — a class of material India imports almost entirely. It is good at the chemistry. It is not yet good at earning on the money that chemistry consumes: return on capital employed was 11.6% in FY26, on a capital base that has grown from ₹678 crore to ₹2,914 crore in four years.
On margins, yes. On the two measures that decide whether a chemical plant was worth building — how full it runs and what it returns — not yet. Gross margin was 49.8% in the June quarter against 47.9% a year before — raw material increases from March were passed through. EBITDA margin 31.5%, and management guides to about 30% for FY27. Utilisation is where the story is unfinished. Strata, the plant dedicated to Baker Hughes, ran at 58% in the June quarter. Ascend reached 72% after a European contract was commercialised there. Magnum, the ₹2,200–2,300 crore mega-site, has one phase online and further blocks to come; management expects it to turn assets 1.5 to 1.75 times when full. Return on capital employed was 11.6% in the year to March 2026, up from 9.7% and 6.7% before it. Rising — and still roughly a third of what the strongest specialty chemical company covered on this site earns. A plant at 58% utilisation is not a bad plant. It is an early one, and that is the whole argument for owning this company or waiting.
Not too much. But the company has quietly stopped being debt-free. At March 2026, borrowings were ₹458 crore against ₹2,456 crore of net worth — a debt-to-equity of 0.19. The point worth noticing is the direction: net cash of ₹373 crore in FY24 became net cash of ₹40 crore in FY25 and net debt of ₹452 crore in FY26. Cash on hand fell to ₹5.66 crore. By 30 June 2026 borrowings were ₹521 crore — ₹421 crore of working capital loans and ₹100 crore of term loans. The working capital half is heavy for a reason: inventory sits at 169 days and receivables at 123 days. Capital spending will be ₹300–350 crore in FY27, of which ₹94 crore went in the June quarter. The balance sheet is not stretched. It is being spent, deliberately, and the IPO money that used to cushion it is gone.
Growing fast, with margins widening — and cash arriving years behind the profit. Revenue rose 38% in the year to March 2026 and 27% in the June quarter. EBITDA margin went from 28.8% to 31.3%, and to 31.5% in the quarter. Profit grew 39%. The gap is what the growth costs. Operating cash flow over three years was ₹226 crore against ₹460 crore of reported profit. Inventory stands at 169 days, receivables at 123. Every rupee of growth is being financed before it is collected.
Fast now. It was not always. Year to March 2026: revenue ₹1,160 crore against ₹839 crore, up 38%. Profit ₹219 crore against ₹158 crore, up 39%. June 2026 quarter: revenue ₹327 crore, up 27% on the same quarter last year and 7% on the March quarter, with profit up 33%. One caveat on that 33%: the final insurance claim for the assets lost in the November 2023 fire was received in the same quarter, so some of it does not repeat. The five-year record is not a straight line. FY24 was a bad year — revenue fell 8% and profit fell 37% — and FY25 recovered 40% and 92%. Over three years revenue compounds at 21% and profit at 19%. Underneath the total, the mix is moving. In the June quarter contract exclusive manufacturing grew about 75% and contract research about 20%, while the company's own large-scale molecules sold 22% fewer tonnes — deliberately, because those production lines were handed to contract customers. Prices on what remained rose 22.5%.
Built, every rupee of it. There have been no acquisitions. Growth has come from putting up plants: gross block ₹853 crore in FY24, ₹1,117 crore in FY25, ₹1,506 crore in FY26 — a third more each year — with another ₹506 crore of construction in progress at March 2026 that earns nothing yet. The sites now have names. Catalyst is research, Genesis and Ascend make both own and contract products, Strata belongs to Baker Hughes, and Magnum at Panoli is the mega-site: sixteen production blocks, ₹2,200–2,300 crore, commissioned in phases with the second due in FY2030. ₹335 crore of capital contracts were signed and not yet executed at March 2026. This is a company still under construction, and it says so.
Improving, and for the right reason. EBITDA margin: 22.1% in FY24, 28.8% in FY25, 31.3% in FY26. In the June quarter, 31.5% against 30.6% a year before. Gross margin in the quarter was 49.8% against 47.9% — March's raw material increases were passed on to customers. Management's explanation is mix, not price. Contract exclusive manufacturing earns 28–30% at EBITDA level and is growing at about 75%; together with contract research it is now 60% of revenue, heading for 70%. Every point of that shift lifts the average. Guidance for FY27 is about 30% — slightly below where the June quarter landed. Read that as management declining to promise the mix will keep improving in a straight line.
This is the weak spot. Return on capital employed was 11.6% in the year to March 2026. Return on equity was 8.9%. Both are rising — ROCE was 6.7% in FY24 and 9.7% in FY25 — and both are low for a business earning 31% EBITDA margins. The arithmetic is not mysterious. Capital employed went from ₹678 crore in FY22 to ₹2,914 crore in FY26, while profit went from ₹109 crore to ₹219 crore. The plant has been built ahead of the demand, on purpose, and the returns are diluted until it fills. Magnum is expected to turn assets 1.5 to 1.75 times once fully operational. Until blocks like that are running, this number stays where it is — and it is the single figure that decides whether the story worked.
No. Not yet. Operating cash flow was ₹142 crore in FY26 against ₹219 crore of profit. Over three years the totals are ₹226 crore of cash against ₹460 crore of profit — 49 paise on the rupee. Before FY25 the number was negative every single year. The money is sitting in the working capital. Inventory was ₹537 crore at March 2026, or 169 days, which the finance director attributes to raw material positioning for Site 3++ and Magnum. Receivables were ₹390 crore, or 123 days, against stated credit terms of 90 days. Debtor days have come down — 145 in FY23, 123 now — and management calls the reduction a clear operational priority. It is the right priority. A company converting half its profit into cash is funding its own growth twice.
A family, four of them on the executive board, holding three-quarters of the company and having pledged none of it. Ashwin Desai is managing director. Purnima Desai, Rohan Desai and Aman Desai are whole-time directors. The board has twelve seats: four executive, two non-executive, six independent. Below them the senior roles are outsiders — the chief technology officer is Dr. James W. Ringer, who spent thirty years at Dow, and the finance director is Faiz Nagariya. The promoter family holds 74.93%, held the identical number of shares in March and June 2026, and has drifted only 0.07 of a point across five quarters. Nothing is pledged. What to weigh against that: the auditor is a Surat firm rather than one of the big four, the family is paid ₹6.7 crore a year between them, and money moves in small amounts to companies the directors control. None of it is large. All of it is disclosed.
A clean opinion, a small auditor, and one line in the notes worth reading twice. Suresh I. Surana & Associates of Surat signed an unmodified opinion on the year to March 2026. The key audit matter was cut-off risk in revenue recognition — whether sales were booked in the right period — which is the usual matter for a company shipping to many countries on different terms. The line to notice is not in the audit report but in the borrowings note: during FY26 the company used ₹212 crore of short-term borrowing for long-term purposes, principally capital expenditure, and capitalised ₹10.5 crore of borrowing cost. It is disclosed, it is reportable under the auditor's order, and the company says it is restructuring the debt to match assets to maturities. Funding a plant on a working capital line is not fraud. It is a company moving faster than its financing. On litigation: a GST show-cause notice for ₹4.3 crore of input credit claimed on IPO expenses, under appeal, with no provision made because management expects to win. Income tax and GST matters are in the appellate process on the same basis.
It sells difficulty. The competition is whoever else can make the molecule, which is often nobody in India. Three ways of selling the same capability: research and manufacture for a customer, dedicated exclusive manufacture under long contracts, and its own large-scale molecules. The first two are 60% of revenue and rising. By end market in the June quarter: pharmaceuticals 32.2%, oil and gas 31.4% — past ₹100 crore in a quarter for the first time — material science 16.6%, agrochemicals 9.5%. Two years ago oil and gas was nothing. What makes it different is the list of people who chose it. Baker Hughes has a dedicated plant. Saudi Aramco co-developed a product. Milliken signed a multi-year supply agreement. Dow picked it as exclusive Indian research partner for silicones. Those are not customers a contract chemist wins on price.
It depends which of its three businesses you mean, and for the newest one the honest answer is nobody in India. Among listed Indian specialty chemical companies covered here, the comparison set is Acutaas Chemicals (₹1,339 crore of revenue, 32.3% return on capital), Navin Fluorine (₹3,314 crore, 21.2%) and Deepak Nitrite (₹7,887 crore, 11.4%). Aether at ₹1,160 crore is the smallest of the four. On return on capital it sits at the bottom with Deepak Nitrite — 11.6% against 11.4% — while the two closest to it in size earn two to three times that. In silicones, the incumbents are global: Dow, Wacker, Momentive, Elkem, Shin-Etsu. India has no manufacturer of the foundational molecules at all — which is the entire premise of the Dow programme. In semiconductor materials, other Indian entrants are chasing fab consumables — high-purity gases, solvents, photoresists, polishing chemicals. Aether is not. It is making the specialty monomer that sits upstream of the coupling agents and resins in high-speed circuit boards: 400 tonnes of capacity, about $50 a kilo, targeted to triple by 2030. The company's answer on Chinese competition is worth the space: it says it has never lost market share on its own molecules even when prices fell 30–35% after COVID.
Helping: the world wants a chemist outside China, and this one keeps being chosen. Ten new customers were onboarded in the June quarter and more than nine customer and certification audits cleared. Management describes urgency from European customers "where the economics of manufacturing at home have become difficult, if not impossible." Contract manufacturing carries 28–30% EBITDA margins and is growing at 75%. Site 3++ reached commercial contribution faster than planned. Over 300 R&D staff, and a new research centre with 120 fume hoods due in FY2028. Hurting: the concentration, and the capital. Baker Hughes alone was ₹70 crore of the ₹327 crore quarter — a fifth of revenue, from one customer, in a plant built for it that is running at 58%. Oil and gas as a whole is 31% of sales and was nothing two years ago. Growth that fast, from that few, cuts both ways. ₹506 crore of plant under construction earns nothing. Return on capital is 11.6%. Half of reported profit is stuck in inventory and receivables. Net cash of ₹373 crore two years ago is net debt of ₹452 crore now, and part of that debt is short-term money funding long-lived assets. Management was asked directly what could derail it and named two things: safety, and its own ability to execute. Both are honest answers. Neither is visible in a quarterly number until it has already happened.
A long-term grower with a cyclical middle. The customer industries — pharmaceuticals, agrochemicals, oil and gas, electronics — do not move together, which is why the sector mix matters. The company has just lived through what its own chairman calls "one of the longest downturns the global chemical industry has witnessed," and FY24 is the scar: revenue down 8%, profit down 37%. The structural part is real. Western chemical companies are shutting high-cost plants; buyers want a source that is not China; India is the default alternative. That is why a 13-year-old Surat company has Baker Hughes, Aramco, Milliken and Dow on its customer list. The cyclical part is equally real, and it shows up as price. Aether's own molecules sold for 30–35% less after COVID, and it kept the volume by not losing share. A business that has to defend price every cycle needs the contracted half of its revenue to keep growing — which is exactly what management says it is doing.
Only if you are buying the plant that has not been built yet. At ₹1,634.40 on 20 August 2026 the shares changed hands at 99 times earnings, 8.8 times book and 18.7 times sales. The earnings yield is 1.0%. The company those multiples are attached to earned 11.6% on capital last year and converted 49 paise of each rupee of profit into cash over three years. Both statements are true at once, and the gap between them is the investment. You are paying a price that assumes Magnum fills, the contract mix reaches 70%, the semiconductor line sells and Dow turns into manufacturing. If those happen, the earnings grow into the multiple. If they arrive late, the multiple has a long way to fall.
Expensive by every measure available, and dearer than anything comparable on this site. On 20 August 2026: ₹1,634.40 a share, ₹21,688 crore of market value, 99 times the year's earnings, 8.8 times book value, 18.7 times sales. A PEG of 5.2 against three-year profit growth. The three other specialty chemical companies covered here trade at 74 times (Acutaas), 64 times (Navin Fluorine) and 43 times (Deepak Nitrite). Aether is the most expensive of the four and the smallest, and its 11.6% return on capital is the lowest but one — only Deepak Nitrite, at 11.4%, is lower, and Deepak trades at 43 times. At an earnings yield of 1.0%, the profits of this business would take a century to repay what the market is asking for it. What you are buying instead is the difference between 11.6% return on capital today and what it becomes when ₹506 crore of unfinished plant starts earning.
Foreign funds have been buying. Domestic funds have been selling. Small shareholders have been leaving. Over the five quarters to June 2026, foreign institutional holding rose from 5.04% to 7.42%. Domestic institutional holding fell from 13.41% to 10.49%, with mutual funds specifically down from 12.30% to 9.68%. Net of each other, institutions hold 0.54 points less of the company than a year ago. The number of individual shareholders fell 10%, from 72,628 to 65,336, while the share price doubled. Public holding as a percentage barely moved, at 7.16%. Read together: fewer people own it, and the ones who remain own more each. Foreign money arrived while domestic money took profit — which is a disagreement about price, not about the business.
We cannot tell you, and the reason is a gap in what we hold. The shareholding filings we have parsed carry the totals — promoter, foreign institutional, domestic institutional, mutual fund, public — but not the schedule of individual holders above 1%. So no named fund or well-known individual investor can be reported here, and we will not guess at one. What can be said is the shape: institutions hold 17.91% between them, of which mutual funds are 9.68%, and the promoter family holds 74.93%. That leaves 7.16% for everyone else, spread across 65,336 shareholders. This resolves when the named-holder schedule is read out of the June 2026 filing.
It raised money once, has never paid a dividend, and is now borrowing instead. The equity history is short and done: the IPO in 2022, then a qualified placement in June 2023 that raised ₹750 crore at ₹936 a share, of which ₹183 crore was earmarked for the Facility 3 expansion and the whole amount reported as used for its stated objects. Share count has been effectively flat since — 13.26 crore in FY24, 13.27 crore now, dilution of 0.08% last year. Employee options outstanding are 432,543 shares, another 0.33%. No dividend has been paid in any of the five years on file. What has changed is the funding. Borrowings went from ₹200 crore to ₹458 crore in FY26, and the notes disclose that ₹212 crore of short-term borrowing was used for long-term purposes — capital expenditure — with ₹10.5 crore of borrowing cost capitalised. The company says it is restructuring that debt into longer-dated arrangements. A growth company that stops issuing shares and starts using working capital lines to build plants has made a choice. It is not yet a problem, but it is a change worth watching.
Loading…